Suppr超能文献

US Incidence and Demographics of Ocular Surface Squamous Neoplasia in the IRIS® Registry 2014-2021.

作者信息

Meide Elise V H, Ferguson Tanner J, Karp Carol L, Lum Flora, Terveen Daniel C

机构信息

University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.

University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota; Vance Thompson Vision, Sioux Falls, South Dakota.

出版信息

Ophthalmology. 2025 Sep;132(9):988-994. doi: 10.1016/j.ophtha.2025.04.014. Epub 2025 Apr 19.

Abstract

PURPOSE

To determine the incidence and demographics of ocular surface squamous neoplasia (OSSN) in the United States using the IRIS® Registry (Intelligence Research in Sight).

DESIGN

Retrospective analysis of all patients with OSSN International Classification of Diseases (ICD) 9 and 10 Revision codes.

PARTICIPANTS

A total of 13 924 unique eyes from 13 383 patients.

METHODS

The ICD 9 and 10 revision codes were used to identify eyes with OSSN.

MAIN OUTCOME MEASURES

Incidence of OSSN, demographic information, diagnosis, risk factors, and frequency of use for current treatments.

RESULTS

The annual incidence from 2014 to 2021 in the IRIS Registry was 3.4 per 100 00 patient-years. The incidence within the registry of OSSN increased 2.9 times from 2014 to 2021. The average age was 67 years, with 88% of patients older than 50 years and 62% older than 65 years. Demographics of the affected cohort were 63.8% male, 65% White, and 10% Hispanic. Forty percent of patients with OSSN had a history of smoking, and 39% of patients were in southern US states based on US Census classification. Surgical excision was performed on 44% of OSSN eyes. Of the patients with primary topical therapy, 62% were treated with interferon (IFN) alfa-2b.

CONCLUSIONS

This study used the IRIS Registry as a database for the incidence and demographics of OSSN. Our demographic results are consistent with other studies showing a higher incidence in older, White, and male patients. This study demonstrated that as of 2021 there are at least 2100 new OSSN cases per year in the United States and that incidence increased from 2014 to 2021. The use of the topical immuno-chemotherapy IFN remained a popular treatment modality for OSSN from 2014 to 2021.

FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

摘要

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验